Abstract: Disclosed herein is a method for the diagnosis/prognosis of a septic syndrome based on a biological sample from a patient. The method may include extracting biological material the biological sample, contacting the biological material with at least one specific reagent that is selected from specific reagents for the target genes having a nucleic acid sequence of any one of SEQ ID NOs: 1 to 28, and determining the expression of at least one of the target genes.

Abstract: An in vitro or ex vivo method for determining the risk of complication in a patient, including a step of measuring the expression of C3AR1 in a biological sample from the patient.

Abstract: The invention relates to an in vitro or ex vivo method for determining the risk of incidence of a care-related infection in a patient, including a step of measuring the expression of CIITA in a biological sample from said patient.

Abstract: An in vitro or ex vivo method for determining the risk of incidence of a care-related infection includes a step of measuring the expression of CD177 in a biological sample from said patient.

Abstract: An in vitro or ex vivo method for determining the risk of incidence of a healthcare-associated infection includes a step of measuring the expression of TAP2 in a biological sample from said patient.

Abstract: An in vitro or ex vivo method, based on the measurement of the expression of cytokine(s), from a patient's blood sample, incubated with a stimulus, for determining the risk of occurrence of a healthcare-associated infection in the patient, within seven days following the day on which the collection of the biological sample has been performed from the patient.

Abstract: An in vitro or ex vivo method for determining the risk of occurrence of a healthcare-associated infection in a patient, including a step of measuring the expression of CX3CR1, in a biological sample of said patient.

Abstract: A method for determining a patient's susceptibility of contracting a nosocomial infection that includes obtaining a biological sample from the patient and extracting biological material from the biological sample; preparing a specific reagent of an expression product of at least one target gene selected from S100A9 and S100A8 target genes; and determining the expression of at least one of the target genes S100A9 and S100A8, where overexpression relative to a specified threshold value indicates susceptibility of contracting a nosocomial infection.

Abstract: The present invention relates to a method for the diagnosis/prognosis of a septic syndrome based on a biological sample from a patient, characterized in that it comprises the following steps: a. biological material is extracted from the biological sample, b. the biological material is brought into contact with at least one specific reagent that is selected from specific reagents for the target genes with a nucleic sequence having any one of SEQ ID Nos 1 to 28; c. the expression of at least one of said target genes is determined.

Abstract: Disclosed herein is a method for the diagnosis/prognosis of a septic syndrome based on a biological sample from a patient. The method may include extracting biological material the biological sample, contacting the biological material with at least one specific reagent that is selected from specific reagents for the target genes having a nucleic acid sequence of any one of SEQ ID NOs: 1 to 28, and determining the expression of at least one of the target genes.

Abstract: A method for the in vitro or ex vivo assessment of the risk of complications in a patient suspected of having an infection, having a SOFA score of less than two, including measuring the level of expression, in a biological sample obtained from said patient, of at least one expression product of the VEGFR2 gene.

Abstract: A method for predicting the risk of developing a disseminated infection in a patient admitted to intensive care having no clinical symptoms of such infection includes: determining a first dose of gelsolin G1 in a biological sample from the patient originating from a first sample taken at time T1, carried out between the day of intensive care admission and 48 hours afterward; determining a second dose of gelsolin G2 in a biological sample from the patient originating from a second sample taken at time T2, carried out two to three days after the first sampling; calculating the variation between the dose of gelsolin G2 and the dose of gelsolin G1, giving a ? value; and comparing the ? value to a threshold value S determined beforehand from two patient populations admitted to intensive care, one not having developed a disseminated infection and the other having developed such an infection.

Abstract: A method for predicting the risk of developing a disseminated infection in a patient admitted to intensive care having no clinical symptoms of such infection includes: determining a first dose of gelsolin G1 in a biological sample from said patient originating from a first sample taken at time T1, carried out between the day of intensive care admission and 48 hours afterward; determining a second dose of gelsolin G2 in a biological sample from said patient originating from a second sample taken at time T2, carried out two to three days after the first sampling; calculating the variation between the dose of gelsolin G2 and the dose of gelsolin G1, giving a ? value; and comparing the ? value to a threshold value S determined beforehand from two patient populations admitted to intensive care, one not having developed a disseminated infection and the other having developed such an infection.

Abstract: A method and a kit for establishing an in vitro prognosis on a patient exhibiting SIRS, the method comprising: (i) measuring the level of expression of the CX3CR1 gene in vitro from the biological material of a patient sample by bringing into contact said sample with a specific reagent of the CX3CR1 gene; and (ii) comparing the expression level of the CX3CR1 gene of the patient to a predetermined expression threshold; wherein (iii) if the expression level of the CX3CR1 gene of the patient is less than the predetermined expression threshold, the survival prognosis of the patient is poor, and if the expression level of the CX3CR1 gene of the patient is greater than the predetermined expression threshold, the survival prognosis of the patient is good.

Abstract: A method and a kit for establishing an in vitro prognosis on a patient exhibiting SIRS, the method comprising: (i) measuring the level of expression of the CX3CR1 gene in vitro from the biological material of a patient sample by bringing into contact said sample with a specific reagent of the CX3CR1 gene; and (ii) comparing the expression level of the CX3CR1 gene of the patient to a predetermined expression threshold; wherein (iii) if the expression level of the CX3CR1 gene of the patient is less than the predetermined expression threshold, the survival prognosis of the patient is poor, and if the expression level of the CX3CR1 gene of the patient is greater than the predetermined expression threshold, the survival prognosis of the patient is good.

Abstract: A method for determining a patient's susceptibility of contracting a nosocomial infection that includes obtaining a biological sample from the patient and extracting biological material from the biological sample; preparing a specific reagent of an expression product of at least one target gene selected from S100A9 and S100A8 target genes; and determining the expression of at least one of the target genes S100A9 and S100A8, where overexpression relative to a specified threshold value indicates susceptibility of contracting a nosocomial infection.

Abstract: The present invention relates to a method for diagnosing and/or predicting a septic syndrome, wherein: a. a biological sample from the patient is made available and biological material is extracted from the biological sample b. at least four specific reagents which are selected from the following specific reagents are made available: reagent which is specific for the target gene IL-10, reagent which is specific for the target gene TGF?, reagent which is specific for the target gene HMG1, reagent which is specific for the target gene T-bet, reagent which is specific for the target gene IL-1?, reagent which is specific for the target gene TNF? and reagent which is specific for the target gene GATA-3 c. the expression of at least four target genes selected from: IL-10, TGF?, HMG1, T-bet, IL-1?, TNF? and GATA-3 is determined. The present invention also relates to a kit for diagnosing and/or predicting a septic syndrome.

Abstract: The present invention relates to a method for the diagnosis/prognosis of a septic syndrome based on a biological sample from a patient, characterized in that it comprises the following steps: a. biological material is extracted from the biological sample, b. the biological material is brought into contact with at least one specific reagent that is selected from specific reagents for the target genes with a nucleic sequence having any one of SEQ ID Nos 1 to 28; c. the expression of at least one of said target genes is determined.

Abstract: The present invention relates to a method for the diagnosis of aspirin intolerance based on a biological sample from a patient, characterized in that it comprises the following steps: a. biological material is extracted from the biological sample, b. the biological material is brought into contact with at least one specific reagent chosen from the reagents specific for the target genes exhibiting a nucleic sequence having any one of SEQ ID Nos. 1 to 25; c. the expression of at least one of said target genes is determined.

Abstract: The present invention relates to a method for diagnosing and/or predicting a septic syndrome, wherein: a. a biological sample from the patient is made available and biological material is extracted from the biological sample b. at least four specific reagents which are selected from the following specific reagents are made available: reagent which is specific for the target gene IL-10, reagent which is specific for the target gene TGF?, reagent which is specific for the target gene HMG1, reagent which is specific for the target gene T-bet, reagent which is specific for the target gene IL-1?, reagent which is specific for the target gene TNF? and reagent which is specific for the target gene GATA-3 c. the expression of at least four target genes selected from: IL-10, TGF?, HMG1, T-bet, IL-1?, TNF? and GATA-3 is determined. The present invention also relates to a kit for diagnosing and/or predicting a septic syndrome.